三星醫療(601567.SH)內部轉讓子公司明州醫院27.78%股權
格隆匯8月24日丨三星醫療(601567.SH)公佈,公司於2020年8月22日召開第五屆董事會第二次會議審議通過了《關於內部轉讓子公司股權的議案》,同意公司全資子公司寧波三星智能電氣有限公司(以下簡稱“三星智能”)以5.11億元作價轉讓其所持寧波明州醫院有限公司(以下簡稱“明州醫院”)27.78%股權,受讓方為公司下屬全資子公司寧波奧克斯醫院投資管理有限公司(以下簡稱“醫院投資”),本次股權轉讓完成後,醫院投資持有明州醫院100%股權。本次股權轉讓的目的是為了優化股權結構,梳理公司體系內的各公司間的股權關係,提高運營效率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.